Titan Medical Granted U.S. Patent for Instrument Insertion and Positioning in Single-Port Robotic Surgery
28 August 2018 - 9:15PM
Titan Medical Inc. (TSX: TMD) (Nasdaq: TMDI) (“Titan” or
the “Company”), a medical device company focused on the
design and development of a robotic surgical system for application
in minimally invasive surgery (“MIS”), announces that it has been
granted U.S. Patent No. 10,058,396, titled “System and Apparatus
for Insertion of an Instrument Into a Body Cavity for Performing a
Surgical Procedure.” The patent covers technology that advances the
ease of use and positioning of robotic surgical systems, including
single-port robotic surgical systems such as the Company’s SPORT
Surgical System. The technology was developed internally at Titan
and was led by Dr. Perry Genova, the Company’s Senior
Vice-President of R&D.
“The granting of this U.S. patent further
enhances Titan’s intellectual property position in single-port
robotic surgery. We developed this technology to provide augmented
data to surgeons and bedside assistants to help facilitate safer
instrument insertion and system positioning, as well as to provide
optimal instrument range-of-motion during surgical procedures. This
technology builds on Titan’s leading expertise in single-port
robotic surgery,” commented David McNally, President and CEO of
Titan Medical. “I commend Dr. Genova for his technical
thought-leadership and congratulate him as being the lead inventor
on this granted patent. We believe the unique attributes presented
in the patented technology will further enable successful
single-port robotic surgery by providing relevant operative field
information for surgeons and bedside assistants, ultimately
benefitting the patients for whom this technology is being
developed.”
The Company envisions expanding its patent
portfolio with the filing of foreign patent applications of similar
scope. With the issuance of this patent, the Company has 26 issued
patents and 60 pending patent applications worldwide.
About Titan Medical Inc.
Titan Medical Inc. is focused on research and
development through to the planned commercialization of
computer-assisted robotic surgical technologies for application in
minimally invasive surgery. The Company is developing the SPORT
Surgical System, a single-port robotic surgical system. The SPORT
Surgical System is comprised of a surgeon-controlled patient cart
that includes a 3D high-definition vision system and
multi-articulating instruments for performing MIS procedures, and a
surgeon workstation that provides an advanced ergonomic interface
to the patient cart and a 3D endoscopic view inside the patient’s
body. Titan intends to initially pursue focused surgical
indications for the SPORT Surgical System, which may include one or
more of gynecologic, urologic, colorectal or general abdominal
procedures.
For more information, please visit the Company’s
website at www.titanmedicalinc.com.
Forward-Looking Statements
This news release contains “forward-looking
statements” which reflect the current expectations of management of
the Company’s future growth, results of operations, performance and
business prospects and opportunities. Wherever possible, words such
as “may”, “would”, “could”, “will”, “anticipate”, “believe”,
“plan”, “expect”, “intend”, “estimate”, “potential for” and similar
expressions have been used to identify these forward-looking
statements. These statements reflect management’s current beliefs
with respect to future events and are based on information
currently available to management. Forward-looking statements
involve significant risks, uncertainties and assumptions. Many
factors could cause the Company’s actual results, performance or
achievements to be materially different from any future results,
performance or achievements that may be expressed or implied by
such forward-looking statements, including, without limitation,
those listed in the “Risk Factors” section of the Company’s Annual
Information Form dated March 31, 2018 (which may be viewed at
www.sedar.com). Should one or more of these risks or uncertainties
materialize, or should assumptions underlying the forward-looking
statements prove incorrect, actual results, performance or
achievements may vary materially from those expressed or implied by
the forward-looking statements contained in this news release.
These factors should be considered carefully, and prospective
investors should not place undue reliance on the forward-looking
statements. Although the forward-looking statements contained in
the news release are based upon what management currently believes
to be reasonable assumptions, the Company cannot assure prospective
investors that actual results, performance or achievements will be
consistent with these forward-looking statements.
Contacts:
LHA Investor Relations Kim Sutton Golodetz(212)
838-3777kgolodetz@lhai.com orBruce Voss(310)
691-7100bvoss@lhai.com
Titan Medical (NASDAQ:TMDI)
Historical Stock Chart
From Apr 2024 to May 2024
Titan Medical (NASDAQ:TMDI)
Historical Stock Chart
From May 2023 to May 2024